The specialist in plasma-derived medicines, 100% owned by the State, faces financial needs exceeding 1 billion euros.
The State comes to the rescue of the French Fractionation and Biotechnologies Laboratory (LFB). The specialist in plasma-derived medicines, 100% owned by the State, faces significant financial needs, exceeding one billion euros. It is currently discussing the conditions of its refinancing with its banking partners and its shareholder, under the aegis of an administrator. In addition to a renegotiation of its debt (863 million euros in 2022) underway with bank creditors, the LFB should be recapitalized again. Already in 2021, the State shareholder had reinjected 500 million euros to enable the LFB to find a way out of its financing needs.
The laboratory is investing in all directions to meet patients’ needs for plasma-derived medicines. Indicated in the treatment of rare and often serious diseases such as hemophilia, primary immune deficiencies or dysimmune neuropathies, these…
This article is reserved for subscribers. You have 81% left to discover.
Do you want to read more?
Unlock all items immediately. No commitment.
Already subscribed? Log in
Coronavirus
Related News :